Medulloblastoma (MB) is the most common pediatric brain tumor arising in the cerebellum and has a propensity to affect younger male patients. Treatment options for MB patients depend upon several factors including, type, stage, and location of the tumor and overall patient health. Common treatment strategies include surgical removal, radiation therapy, chemotherapy, pharmacological treatment, and stem cell/bone marrow transplantation. However, patients are at risk for side effects including neurocognitive impairment and endocrine disabilities. Unfortunately, like many other cancers, accurate tumor detection, tumor metastasis, and drug resistance are a serious issue, and until today, no effective solutions are proposed to solve the above problems in MB. The primary focus of this project is to identify molecular markers used to differentiate medulloblastoma subtypes in cerebrospinal fluid (CSF). Identification of such markers is necessary to predict outcomes, understand disease progression using minimally invasive procedures and pursue new therapy options. The CSF samples necessary to complete this work will be provided by the Children’s Brain Tumor Network.
What are the goals of this project?
Researchers aim to identify molecular markers identifiable in CSF samples that could be used to classify medulloblastoma subtypes and provide improved diagnostics, prognostics and monitor outcomes.
What is the impact of this project?
Validating the use of such molecular markers is necessary to move forward in the development of therapeutic options.
Why is the CBTN request important to this project?
This work requires CSF samples made accessible through the Children’s Brain Tumor Network.
The Children's Brain Tumor Network contributed to this project by providing cerebral spinal fluid samples.
Ranjan Perera, PhD
Dr. Perera is director of the Center for RNA Biology at Johns Hopkins All Children's Hospital, a senior scientist in the Cancer & Blood Disorders Institute and an associate professor of oncology in the Johns Hopkins University School of Medicine. He also has a secondary affiliation with the Johns Ho
Johns Hopkins Medicine
Stacie Stapleton, MD
Dr. Stapleton is the director of pediatric neuro-oncology at Johns Hopkins All Children’s Hospital. Dr. Stapleton joined the hospital in 2007 and is double-board certified by the American Board of Pediatrics in general pediatrics and pediatric hematology/oncology. She has formal training in pediatri
Johns Hopkins Medicine
Johns Hopkins MedicineJoined on
Headquartered in Baltimore, Maryland, Johns Hopkins Medicine unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. Johns Hopkins Medicine has six academic and co
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature